Compare Stocks: ORGO, SLDB, ABUS, and DSGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.67 +2.0%	$4.56	$3.31 ▼ $5.38	$904.72M	0.64	1.30 million shs	1.44 million shs
DSGN Design Therapeutics	$14.83 +3.1%	$13.12	$4.68 ▼ $17.25	$900.55M	1.63	440,906 shs	259,839 shs
ORGO Organogenesis	$1.79 +1.7%	$2.37	$1.54 ▼ $7.08	$226.47M	1.34	928,661 shs	547,614 shs
SLDB Solid Biosciences	$9.20 +1.3%	$8.76	$3.79 ▼ $11.45	$973.60M	2.41	979,023 shs	759,298 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+1.97%	+0.86%	+2.41%	+10.14%	+38.58%
DSGN Design Therapeutics	+3.06%	+6.00%	+9.69%	+3.20%	+173.62%
ORGO Organogenesis	+1.70%	-3.76%	-28.11%	-25.73%	-63.54%
SLDB Solid Biosciences	+1.32%	+9.65%	-4.37%	+32.95%	+37.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.67 +2.0%	$4.56	$3.31 ▼ $5.38	$904.72M	0.64	1.30 million shs	1.44 million shs
DSGN Design Therapeutics	$14.83 +3.1%	$13.12	$4.68 ▼ $17.25	$900.55M	1.63	440,906 shs	259,839 shs
ORGO Organogenesis	$1.79 +1.7%	$2.37	$1.54 ▼ $7.08	$226.47M	1.34	928,661 shs	547,614 shs
SLDB Solid Biosciences	$9.20 +1.3%	$8.76	$3.79 ▼ $11.45	$973.60M	2.41	979,023 shs	759,298 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+1.97%	+0.86%	+2.41%	+10.14%	+38.58%
DSGN Design Therapeutics	+3.06%	+6.00%	+9.69%	+3.20%	+173.62%
ORGO Organogenesis	+1.70%	-3.76%	-28.11%	-25.73%	-63.54%
SLDB Solid Biosciences	+1.32%	+9.65%	-4.37%	+32.95%	+37.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	2.50	Moderate Buy	$5.00	7.07% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	11.26% Upside
ORGO Organogenesis	1.67	Reduce	$4.33	142.09% Upside
SLDB Solid Biosciences	2.91	Moderate Buy	$17.11	85.99% Upside

Current Analyst Ratings Breakdown

Latest ORGO, SLDB, ABUS, and DSGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/7/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/7/2026	ORGO Organogenesis	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$3.00 ➝ $2.00
7/17/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	DSGN Design Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SLDB Solid Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/3/2026	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $25.00
5/28/2026	ORGO Organogenesis	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$3.00
5/28/2026	ORGO Organogenesis	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$3.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$181.72M	5.08	N/A	N/A	$1.31 per share	3.56
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.23 per share	N/A
ORGO Organogenesis	$454.61M	0.51	$0.66 per share	2.72	$1.15 per share	1.56
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$3.49 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$33.50M	$0.79	5.91	N/A	N/A	84.22%	90.98%	82.34%	N/A
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	N/A
ORGO Organogenesis	$37.03M	-$0.86	N/A	N/A	N/A	-19.94%	-23.89%	-11.13%	N/A
SLDB Solid Biosciences	-$174.32M	-$1.91	N/A	N/A	N/A	N/A	-71.35%	-60.58%	11/2/2026 (Estimated)

Latest ORGO, SLDB, ABUS, and DSGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ABUS Arbutus Biopharma	-$0.02	-$0.03	-$0.01	-$0.03	$0.70 million	$1.01 million
8/6/2026	Q2 2026	ORGO Organogenesis	-$0.35	-$0.71	-$0.36	-$0.77	$54.27 million	$43.76 million
8/6/2026	Q2 2026	SLDB Solid Biosciences	-$0.4624	-$0.38	+$0.0824	-$0.38	N/A	N/A
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	81.42	54.26
DSGN Design Therapeutics	N/A	18.86	18.86
ORGO Organogenesis	0.07	3.52	3.00
SLDB Solid Biosciences	N/A	13.82	13.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
DSGN Design Therapeutics	56.64%
ORGO Organogenesis	49.57%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	19.90%
DSGN Design Therapeutics	17.10%
ORGO Organogenesis	18.80%
SLDB Solid Biosciences	2.66%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	197.54 million	158.23 million	Optionable
DSGN Design Therapeutics	40	62.58 million	51.88 million	Optionable
ORGO Organogenesis	950	128.68 million	104.48 million	Optionable
SLDB Solid Biosciences	100	107.22 million	104.37 million	Optionable

ORGO, SLDB, ABUS, and DSGN Headlines

Recent News About These Companies

Q3 EPS Forecast for Solid Biosciences Increased by Analyst

August 14 at 1:28 AM | americanbankingnews.com

HC Wainwright Has Positive Estimate for SLDB Q3 Earnings

August 12 at 6:11 AM | marketbeat.com

Dimensional Fund Advisors LP Acquires 277,051 Shares of Solid Biosciences Inc. $SLDB

August 11, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Solid Biosciences (SLDB)

August 8, 2026 | theglobeandmail.com

Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.08 EPS

August 7, 2026 | marketbeat.com

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026 | finance.yahoo.com

Solid Biosciences (SLDB) Expected to Release Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Janus Henderson Group PLC Acquires Shares of 4,010,695 Solid Biosciences Inc. $SLDB

August 3, 2026 | marketbeat.com

Stempoint Capital LP Purchases New Position in Solid Biosciences Inc. $SLDB

July 30, 2026 | marketbeat.com

Solid Biosciences Inc. $SLDB Holdings Boosted by Redmile Group LLC

July 29, 2026 | marketbeat.com

Solid Biosciences Inc. $SLDB Shares Purchased by Ally Bridge Group NY LLC

July 29, 2026 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Moderate Buy" by Analysts

July 26, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)

July 7, 2026 | theglobeandmail.com

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

July 2, 2026 | seekingalpha.com

Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?

July 1, 2026 | finance.yahoo.com

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 8, 2026 | seekingalpha.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 1, 2026 | globenewswire.com

Solid Biosciences to Participate at Upcoming Investor Conferences

June 1, 2026 | globenewswire.com

J.P. Morgan Reaffirms Their Buy Rating on Solid Biosciences (SLDB)

May 24, 2026 | theglobeandmail.com

Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

May 20, 2026 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), SELLAS Life Sciences Group (SLS) and Legend Biotech (LEGN)

May 14, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, SLDB, ABUS, and DSGN Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$4.67 +0.09 (+1.97%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$4.67 +0.00 (+0.09%)

As of 08/14/2026 07:58 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Design Therapeutics NASDAQ:DSGN

$14.83 +0.44 (+3.06%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$14.81 -0.02 (-0.13%)

As of 08/14/2026 07:34 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Organogenesis NASDAQ:ORGO

$1.79 +0.03 (+1.70%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.79 0.00 (-0.06%)

As of 08/14/2026 07:59 PM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Solid Biosciences NASDAQ:SLDB

$9.20 +0.12 (+1.32%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$9.26 +0.07 (+0.71%)

As of 08/14/2026 07:38 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORGO, SLDB, ABUS, and DSGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORGO, SLDB, ABUS, and DSGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORGO, SLDB, ABUS, and DSGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, SLDB, ABUS, and DSGN Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Design Therapeutics NASDAQ:DSGN

Organogenesis NASDAQ:ORGO

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORGO, SLDB, ABUS, and DSGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORGO, SLDB, ABUS, and DSGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORGO, SLDB, ABUS, and DSGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, SLDB, ABUS, and DSGN Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Design Therapeutics NASDAQ:DSGN

Organogenesis NASDAQ:ORGO

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools